Abstract
Diabetes (Type 1 and Type 2) is the most burdensome condition for the healthcare systems worldwide. Continuous glucose monitoring (CGM) is a powerful tool in the management of diabetes that has helped patients with diabetes to achieve better glycemic control as compared to traditional systems. It helps reduce the frequency as well as the severity of hypoglycemia. Continuous glucose monitoring technology is an integral part of the ‘artificial pancreas’. This review provides an overview of CGM technology and its applications.
Keywords: Hypoglycemia, glucose, diabetes, artificial pancreas, CGM, glycemic control.
[1]
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 2019; 157: 107843.
[http://dx.doi.org/10.1016/j.diabres.2019.107843]
[http://dx.doi.org/10.1016/j.diabres.2019.107843]
[2]
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl. 1): S61-70.
[http://dx.doi.org/10.2337/dc19-S006] [PMID: 30559232]
[http://dx.doi.org/10.2337/dc19-S006] [PMID: 30559232]
[3]
Singh H, Venkatesan V. Treatment of ‘Diabesity’: Beyond pharmacotherapy. Curr Drug Targets 2018; 19(14): 1672-82.
[http://dx.doi.org/10.2174/1389450119666180621093833] [PMID: 29929463]
[http://dx.doi.org/10.2174/1389450119666180621093833] [PMID: 29929463]
[4]
Singh H, Venkatesan V. Beta-cell management in type 2 diabetes: Beneficial role of nutraceuticals. Endocr Metab Immune Disord Drug Targets 2016; 16(2): 89-98.
[http://dx.doi.org/10.2174/1871530316666160728091534] [PMID: 27468767]
[http://dx.doi.org/10.2174/1871530316666160728091534] [PMID: 27468767]
[5]
Kiran SG, Dorisetty RK, Umrani MR, et al. Pyridoxal 5′ phosphate protects islets against streptozotocin-induced beta-cell dysfunction-in vitro and in vivo. Exp Biol Med (Maywood) 2011; 236(4): 456-65.
[http://dx.doi.org/10.1258/ebm.2011.010361] [PMID: 21464101]
[http://dx.doi.org/10.1258/ebm.2011.010361] [PMID: 21464101]
[6]
Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007; 117(4): 868-70.
[http://dx.doi.org/10.1172/JCI31669] [PMID: 17404614]
[http://dx.doi.org/10.1172/JCI31669] [PMID: 17404614]
[7]
Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the appropriate continuous glucose monitoring system - a practical approach. Eur Endocrinol 2018; 14(1): 24-9.
[http://dx.doi.org/10.17925/EE.2018.14.1.24] [PMID: 29922348]
[http://dx.doi.org/10.17925/EE.2018.14.1.24] [PMID: 29922348]
[8]
Klonoff DC, Parkes JL, Kovatchev BP, et al. Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care 2018; 41(8): 1681-8.
[http://dx.doi.org/10.2337/dc17-1960] [PMID: 29898901]
[http://dx.doi.org/10.2337/dc17-1960] [PMID: 29898901]
[9]
DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 2018; 19 (Suppl. 27): 105-14.
[http://dx.doi.org/10.1111/pedi.12737] [PMID: 30058221]
[http://dx.doi.org/10.1111/pedi.12737] [PMID: 30058221]
[10]
Burge MR, Mitchell S, Sawyer A, Schade DS. Continuous glucose monitoring: The future of diabetes management. Diabetes Spectr 2008; 21(2): 112-9.
[http://dx.doi.org/10.2337/diaspect.21.2.112]
[http://dx.doi.org/10.2337/diaspect.21.2.112]
[11]
Klonoff DC, Ahn D, Drincic A. Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Res Clin Pract 2017; 133: 178-92.
[http://dx.doi.org/10.1016/j.diabres.2017.08.005] [PMID: 28965029]
[http://dx.doi.org/10.1016/j.diabres.2017.08.005] [PMID: 28965029]
[12]
Cobelli C, Renard E, Kovatchev B. Artificial pancreas: Past, present, future. Diabetes 2011; 60(11): 2672-82.
[http://dx.doi.org/10.2337/db11-0654] [PMID: 22025773]
[http://dx.doi.org/10.2337/db11-0654] [PMID: 22025773]
[13]
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care 2019; 42(8): 1593-603.
[http://dx.doi.org/10.2337/dci19-0028] [PMID: 31177185]
[http://dx.doi.org/10.2337/dci19-0028] [PMID: 31177185]
[14]
Shah R, McKinlay CJD, Harding JE. Neonatal hypoglycemia: Continuous glucose monitoring. Curr Opin Pediatr 2018; 30(2): 204-8.
[http://dx.doi.org/10.1097/MOP.0000000000000592] [PMID: 29346140]
[http://dx.doi.org/10.1097/MOP.0000000000000592] [PMID: 29346140]
[15]
Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101(11): 3922-37.
[http://dx.doi.org/10.1210/jc.2016-2534] [PMID: 27588440]
[http://dx.doi.org/10.1210/jc.2016-2534] [PMID: 27588440]
[16]
Sherr JL, Tauschmann M, Battelino T, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. Pediatr Diabetes 2018; 19 (Suppl. 27): 302-25.
[http://dx.doi.org/10.1111/pedi.12731] [PMID: 30039513]
[http://dx.doi.org/10.1111/pedi.12731] [PMID: 30039513]
[17]
Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American association of clinical endocrinologists and American College of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocr Pract 2018; 24(3): 302-8.
[http://dx.doi.org/10.4158/PS-2017-0155] [PMID: 29547046]
[http://dx.doi.org/10.4158/PS-2017-0155] [PMID: 29547046]
[18]
National Clinical Guideline Centre (UK). Type 1 Diabetes in Adults: Diagnosis and Management London. UK: National Institute for Health and Care Excellence 2015. Available from: https://www.nice.org.uk/guidance/ng17
[19]
Klonoff DC, et al. Continous glucose monitoring: An endocrine society clinical practice guideline. J Clin Endcrinol Metab 2011; 96(10): 2968-79.
[20]
Rodbard D. Continuous Glucose Monitoring: A review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 2017; 19(S3): S25-37.
[http://dx.doi.org/10.1089/dia.2017.0035] [PMID: 28585879]
[http://dx.doi.org/10.1089/dia.2017.0035] [PMID: 28585879]
[21]
Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: A real-world study. J Clin Endocrinol Metab 2018; 103(3): 1224-32.
[http://dx.doi.org/10.1210/jc.2017-02498] [PMID: 29342264]
[http://dx.doi.org/10.1210/jc.2017-02498] [PMID: 29342264]
[22]
Houlder SK, Yardley JE. Continuous glucose monitoring and exercise in type 1 diabetes: Past, present and future. Biosensors (Basel) 2018; 8(3): 73.
[http://dx.doi.org/10.3390/bios8030073] [PMID: 30081478]
[http://dx.doi.org/10.3390/bios8030073] [PMID: 30081478]
[23]
Klonoff DC. Continuous glucose monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care 2005; 28(5): 1231-9.
[http://dx.doi.org/10.2337/diacare.28.5.1231] [PMID: 15855600]
[http://dx.doi.org/10.2337/diacare.28.5.1231] [PMID: 15855600]
[24]
Dye L, Mansfield M, Lasikiewicz N, et al. Correspondence of continuous interstitial glucose measurement against arterialised and capillary glucose following an oral glucose tolerance test in healthy volunteers. Br J Nutr 2010; 103(1): 134-40.
[http://dx.doi.org/10.1017/S0007114509991504] [PMID: 19674490]
[http://dx.doi.org/10.1017/S0007114509991504] [PMID: 19674490]
[25]
Palmisano F, Zambonin PG, Centonze D, Quinto M. A disposable, reagentless, third-generation glucose biosensor based on overoxidized poly(pyrrole)/tetrathiafulvalene-tetracyanoquinodimethane composite. Anal Chem 2002; 74(23): 5913-8.
[http://dx.doi.org/10.1021/ac0258608] [PMID: 12498183]
[http://dx.doi.org/10.1021/ac0258608] [PMID: 12498183]
[26]
Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013; 15(3): 198-211.
[http://dx.doi.org/10.1089/dia.2013.0051] [PMID: 23448694]
[http://dx.doi.org/10.1089/dia.2013.0051] [PMID: 23448694]
[27]
Aberer F, Hajnsek M, Rumpler M, et al. Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. Diabetes Obes Metab 2017; 19(7): 1051-5.
[http://dx.doi.org/10.1111/dom.12907] [PMID: 28205324]
[http://dx.doi.org/10.1111/dom.12907] [PMID: 28205324]
[28]
Maddaloni E, Coraggio L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R. Effects of COVID-19 lockdown on glucose control: Continuous glucose monitoring data from people with diabetes on intensive insulin therapy. Diabetes Care 2020; 43(8): e86-7.
[http://dx.doi.org/10.2337/dc20-0954] [PMID: 32503838]
[http://dx.doi.org/10.2337/dc20-0954] [PMID: 32503838]
[29]
Gupta R, Hussain A, Misra A. Diabetes and COVID-19: Evidence, current status and unanswered research questions. Eur J Clin Nutr 2020; 74(6): 864-70.
[http://dx.doi.org/10.1038/s41430-020-0652-1] [PMID: 32404898]
[http://dx.doi.org/10.1038/s41430-020-0652-1] [PMID: 32404898]
[30]
Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 2015; 17(3): 177-86.
[http://dx.doi.org/10.1089/dia.2014.0272] [PMID: 25436913]
[http://dx.doi.org/10.1089/dia.2014.0272] [PMID: 25436913]
[31]
Jacobs PG, El Youssef J, Reddy R, et al. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab 2016; 18(11): 1110-9.
[http://dx.doi.org/10.1111/dom.12707] [PMID: 27333970]
[http://dx.doi.org/10.1111/dom.12707] [PMID: 27333970]
[32]
Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019; 381(18): 1707-17.
[http://dx.doi.org/10.1056/NEJMoa1907863] [PMID: 31618560]
[http://dx.doi.org/10.1056/NEJMoa1907863] [PMID: 31618560]
[33]
Riddell M, Perkins BA. Exercise and glucose metabolism in persons with diabetes mellitus: Perspectives on the role for continuous glucose monitoring. J Diabetes Sci Technol 2009; 3(4): 914-23.
[http://dx.doi.org/10.1177/193229680900300439] [PMID: 20144341]
[http://dx.doi.org/10.1177/193229680900300439] [PMID: 20144341]
[34]
Jayawardene DC, McAuley SA, Horsburgh JC, et al. Closed-loop insulin delivery for adults with type 1 diabetes undertaking high-intensity interval exercise versus moderate-intensity exercise: A randomized, crossover study. Diabetes Technol Ther 2017; 19(6): 340-8.
[http://dx.doi.org/10.1089/dia.2016.0461] [PMID: 28574723]
[http://dx.doi.org/10.1089/dia.2016.0461] [PMID: 28574723]
[35]
Himadri S. Postmarketing surveillance of in-vitro diagnostic system in the European Union. Appl Clin Res Clin Trials Regul Aff 2021; 8(1): 48-52.
[http://dx.doi.org/10.2174/2213476X07666201013161551]
[http://dx.doi.org/10.2174/2213476X07666201013161551]
[36]
Meng R, Gu T, Yang F, Liu J, Sun Q, Zhu D. Performance evaluation of the glunovo® continuous blood glucose monitoring system in Chinese participants with diabetes: A multicenter, self-controlled trial. Diabetes Ther 2021; 12(12): 3153-65.
[http://dx.doi.org/10.1007/s13300-021-01171-2] [PMID: 34704201]
[http://dx.doi.org/10.1007/s13300-021-01171-2] [PMID: 34704201]
[37]
Joseph JI. Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems. J Diabetes Sci Technol 2021; 15(1): 167-73.
[http://dx.doi.org/10.1177/1932296820911919] [PMID: 32345047]
[http://dx.doi.org/10.1177/1932296820911919] [PMID: 32345047]
[38]
DeJournett J, Nekludov M, DeJournett L, Wallin M. Performance of a closed-loop glucose control system, comprising a continuous glucose monitoring system and an AI-based controller in swine during severe hypo- and hyperglycemic provocations. J Clin Monit Comput 2021; 35(2): 317-25.
[http://dx.doi.org/10.1007/s10877-020-00474-2] [PMID: 32006145]
[http://dx.doi.org/10.1007/s10877-020-00474-2] [PMID: 32006145]
[39]
Faulds ER, Jones L, McNett M, et al. Facilitators and barriers to nursing implementation of Continuous Glucose Monitoring (CGM) in critically ill patients with COVID-19. Endocr Pract 2021; 27(4): 354-61.
[http://dx.doi.org/10.1016/j.eprac.2021.01.011] [PMID: 33515756]
[http://dx.doi.org/10.1016/j.eprac.2021.01.011] [PMID: 33515756]
[40]
van Doorn WP, Foreman YD, Schaper NC, et al. Machine learning-based glucose prediction with use of continuous glucose and physical activity monitoring data: The Maastricht Study. PLoS One 2021; 16(6): e0253125.
[http://dx.doi.org/10.1371/journal.pone.0253125]
[http://dx.doi.org/10.1371/journal.pone.0253125]
[41]
Noaro G, Cappon G, Sparacino G, Boscari F, Bruttomesso D, Facchinetti A. Methods for insulin bolus adjustment based on the continuous glucose monitoring trend arrows in type 1 diabetes: Performance and safety assessment in an in silico clinical trial. J Diabetes Sci Technol 2021; 19322968211043162.
[http://dx.doi.org/10.1177/19322968211043162] [PMID: 34486426]
[http://dx.doi.org/10.1177/19322968211043162] [PMID: 34486426]
Article Metrics
3